NOTIFICATION OF BOARD MEETING

VOLUNTARY ANNOUNCEMENT - POSITIVE RESULTS ON PHASE III CLINICAL STUDY OF TQB3454 "IDH1 INHIBITOR" FOR BILIARY TRACT CANCER

VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL ON TQB3205 “PAN-KRAS INHIBITOR” APPROVED BY THE NMPA

VOLUNTARY ANNOUNCEMENT - EXCLUSIVE LICENSE AGREEMENT FOR ROVADICITINIB WITH SANOFI

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 28 FEBRUARY 2026

VOLUNTARY ANNOUNCEMENT - “ROVADICITINIB TABLET” APPROVED FOR MARKETING

VOLUNTARY ANNOUNCEMENT - APPROVAL FOR MARKETING OF BENMELSTOBART INJECTION FOR THE INDICATION OF MAINTENANCE THERAPY AFTER CHEMORADIOTHERAPY FOR NON-SMALL CELL LUNG CANCER

VOLUNTARY ANNOUNCEMENT - COMPLETION OF SUBJECT ENROLLMENT IN PHASE III CLINICAL TRIAL OF TQB2102 “HER2 BISPECIFIC ADC” FOR HER2-LOW BREAST CANCER